Owning the high incidence and disability rate in modern society, to be expected, cardiovascular
diseases (CVDs) have become the global and most fatal cause nowadays. Currently, induced
pluripotent stem cells (iPSCs), with the potential to form fresh myocardium and better safety than
other stem cells, existed widely in the CVD therapy studies. Simultaneously, iPSC-derived cardiomyocytes
(CMs), as a novel disease model, appear to play a significant role in new drug screening,
drug safety assessment, along with the pathological mechanisms of diseases. Based on rigorous molecular
and functional characterization, the accuracy of experimental researches are guaranteed and
thus several underlying pathogenesis for the treatment of CVDs by iPSCs were published, such as enrichment
of paracrine factors, regulation of miRNAs, mechanical support of new tissues, activation of
specific pathways and specific enzymes, etc. Furthermore, a few chemical small molecules and suitable
biological scaffolds remained contributors in enhancing the efficiency of iPSC transplantation.
This article reviews the development courses and limitations of iPSCs in CVD therapy, and summarizes
in category the latest research achievements from iPSCs.